SerpinB3, a biomarker of taxane benefit in breast cancer

Elaina Susan Renata Collie-Duguid, Kathleen Sweeney, Keith Nicol Stewart, Iain D Miller, Steven Darryll Heys

Research output: Contribution to journalAbstract


Background: Lysosomal cathepsin proteases function in a pro-
grammed cell death (LPCD) pathway. Although there is evidence
for the importance of this pathway in cancer cell survival, it has
not been exploited in anti-cancer therapeutics. Hsp70 and ser-
pinB3 can block this pathway and promote cell survival. Further-
more, serpinB3 is associated with lack of response to
chemotherapy. Cathepsin mediated cell death is observed in
response to anthracyclines or taxanes, which are widely utilised
in breast cancer treatment.
Original languageEnglish
Article numberO-35
Pages (from-to)13
Number of pages1
JournalEuropean Journal of Cancer. Supplement
Issue number6
Publication statusPublished - Sep 2010
Event1st British Breast Cancer Research Conference - Nottingham, United Kingdom
Duration: 15 Sep 201017 Sep 2010


  • Breast cancer
  • treatment
  • biomarkers
  • serpinB3


Dive into the research topics of 'SerpinB3, a biomarker of taxane benefit in breast cancer'. Together they form a unique fingerprint.

Cite this